The Impact of Patient and Operative Factors on the Development of Gastroesophageal Reflux Disease after Bariatric Surgery

2016 ◽  
Vol 223 (4) ◽  
pp. e76
Author(s):  
Hatim A. Alsulaim ◽  
Robin D. Megill ◽  
Joseph K. Canner ◽  
Aslam Ejaz ◽  
Leigh A. Peterson ◽  
...  
2020 ◽  
Vol 11 (4) ◽  
pp. 134-139
Author(s):  
Robin Mauricio Yance Hurtado ◽  
Thiago Ferreira de Souza ◽  
Manoel dos Passos Galvão Neto ◽  
Eduardo Grecco ◽  
Sergio A Barrichello Junior ◽  
...  

Author(s):  
Chia-Liang Wu ◽  
Chien-Lin Chen ◽  
Shu-Hui Wen

Given the frequent concomitance between depression and gastroesophageal reflux disease (GERD), it is important to evaluate the change of depression in patients with GERD, especially considering the presence of esophageal mucosal breaks (MB). This study aimed to examine the change in the levels of depression in patients with GERD during proton-pump inhibitors (PPI) therapy. We designed a prospective cohort study to explore the profile of the alteration in depression with respect to the impact of esophageal MB. This study recruited 172 eligible patients with GERD between February 2016 and May 2018. The change in depression was defined as the difference between the respective Taiwanese Depression Questionnaire (TDQ) scores obtained at baseline and after PPI therapy. Multivariate linear regression models were used to estimate the factors associated with the change in depression. The results revealed statistically significant improvements in the TDQ score (mean score: baseline = 13.2, after PPI therapy = 10.9, p < 0.01, Cohen’s d = 0.30) during PPI therapy for GERD. Moreover, the MB was an independent variable associated with changes in the TDQ score [B = 3.31, 95% confidence interval (CI): (1.12, 5.51), p < 0.01] and the improvement in depression [odds ratio = 0.38, 95% CI: (0.17, 0.86), p = 0.02]. Our findings revealed that depressive symptoms improved slightly following PPI therapy. Moreover, MB was an unfavorable prognostic factor for the improvement in depression.


2018 ◽  
Vol 28 (10) ◽  
pp. 3080-3086 ◽  
Author(s):  
John P. Kuckelman ◽  
Cody J. Phillips ◽  
Michael J. Derickson ◽  
Byron J. Faler ◽  
Matthew J. Martin

2019 ◽  
Vol 34 (4) ◽  
pp. 1812-1818 ◽  
Author(s):  
Rhys Kavanagh ◽  
Jessica Smith ◽  
Umair Bashir ◽  
Dana Jones ◽  
Emily Avgenakis ◽  
...  

2019 ◽  
Vol 32 (5) ◽  
Author(s):  
J L Horsley-Silva ◽  
S B Umar ◽  
M F Vela ◽  
W L Griffing ◽  
J M Parish ◽  
...  

2019 ◽  
pp. 014556131989246
Author(s):  
Jerome R. Lechien ◽  
Gersende Debie ◽  
Virginie Mahillon ◽  
Marie-Paule Thill ◽  
Alexandra Rodriguez ◽  
...  

Objectives: To compare the 2 long-term medical strategies in chronic rhinosinusitis without nasal polyps (CRSnNP) and to identify the role of gastroesophageal reflux disease (GERD) and Helicobacter pylori as factors of treatment failure. Material and Methods: Fifty-seven patients with CRSnNP were randomized into 2 therapeutic groups. The first group was treated with 4 weeks of amoxicillin/clavulanate and a short course of oral steroids. The second group received 8 weeks of clarithromycin. Sinonasal Outcome Test-20 (SNOT-20) and Lund and Mackay scores were assessed at baseline and after treatment, and GERD Health-Related Quality of Life (GERD-HRQL) questionnaire was evaluated in all patients. Patients with a GERD-HRQL score >8 received esogastroscopy and H pylori detection. Patients were followed during a 10-year period for clinical course and GERD evolution. The 10-year evolution of patients was described in terms of recurrence, medical, and surgical treatments. Results: Thirty-seven patients completed the study; SNOT-20 and Lund and Mackay scores similarly improved in both groups. Amoxicillin/clavulanate group had significantly more adverse reactions than the clarithromycin group (P = .03). After the therapeutic course, 35% (amoxicillin/clavulanate) and 41% (clarithromycin) of patients needed functional endoscopic sinus surgery (FESS). During the long-term follow-up, 54% (amoxicillin/clavulanate) and 40% (clarithromycin) of patients had late CRSnNP recurrence; FESS was performed in less than 15% of cases of recurrence. Gastroesophageal reflux disease complaint’s severity was associated with late recurrence of CRSnNP. Conclusion: Amoxicillin/clavulanate and clarithromycin would be competitive treatments for CRSnNP. Gastroesophageal reflux disease seems to be a negative factor for treatment response and recurrence.


Sign in / Sign up

Export Citation Format

Share Document